Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.

Biological & pharmaceutical bulletin - 1 Jan 2018

Yokoyama Takeshi, Mizuguchi Mineyuki

Abstract excerpt

Hereditary transthyretin (TTR)-related amyloidosis is caused by mutations in the TTR gene. The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis. In this review, we summarized the natural products and synthetic compounds that have been shown to inhibit the amyloidogenesis of TTR. The stabilizers and/or the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid
Share to Amyloidosis
Share to Anti-Inflammatory Agents, Non-Steroidal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Products

Share to TTR gene

Share to Mutation

Share to Prealbumin

Source

Identifiers

PMID: 29962408
DOI: 10.1248/bpb.b18-00166

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.PMID 29962408Read ↗

Transthyretin: Its function and amyloid formation.Semantic proximity Read ↗

Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.Semantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.Semantic proximity Read ↗

Targeting Amyloid Aggregation: An Overview of Strategies and MechanismsSemantic proximity Read ↗

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Semantic proximity Read ↗

Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.Semantic proximity Read ↗

Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione.Semantic proximity Read ↗

Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.Semantic proximity Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Transthyretin Mimetics as Anti-β-Amyloid Agents: A Comparison of Peptide and Protein Approaches.Semantic proximity Read ↗

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.